| Agennix is a privately owned Houston-based biopharmaceutical company. It
is the world leader in the development of recombinant human lactoferrin
(rhLF), a natural immuno-stimulatory and anti-inflammatory protein, and a
variety of patented peptides. RhLF has been administered to over 240 people
without a single drug-related serious adverse event, and has demonstrated
potency in treating cancer, asthma and infections. Agennix is the first and
only company to manufacture substantial quantities of human lactoferrin and
holds global patents on its technology, with 40 issued patents and 65 patents
pending. In 2002, Agennix will initiate or complete five Phase II clinical
trials in indications including the treatment of cancer, the treatment of
infections in chemotherapy patients, and the treatment of asthma. |
